PLUVICTO® is the first and only approved targeted radiopharmaceutical therapy for the treatment of adult patients with a certain type of advanced cancer called prostate specific membrane antigen (PSMA) that has spread to other parts of the body. PLUVICTO® is used in patients who have already been treated with other anti-cancer treatments.


Before you receive PLUVICTO® you must have a scan to identify the tumors that express PSMA. PLUVICTO® is administered through infusion every six weeks for up to six doses, or until disease progression or unacceptable toxicity. Patients should drink plenty of water prior to infusion in order to urinate as often as possible during the first hours after administration.


  • Improves progression of PSMA metastatic cancer